Agreements - Novartis (Details)	1 Months Ended						3 Months Ended								12 Months Ended					33 Months Ended
	May 31, 2015 USD ($)	Jan. 31, 2015 USD ($)	Oct. 31, 2014 USD ($) item	Nov. 30, 2013 USD ($)	Oct. 31, 2013 USD ($)	Mar. 31, 2013 USD ($) item	Jun. 30, 2016 USD ($)	Mar. 31, 2016 USD ($)	Dec. 31, 2015 USD ($)	Sep. 30, 2015 USD ($)	Jun. 30, 2015 USD ($)	Mar. 31, 2015 USD ($)	Dec. 31, 2014 USD ($)	Sep. 30, 2014 USD ($)	Jun. 30, 2016 USD ($) item	Jun. 30, 2015 USD ($)	Jun. 30, 2014 USD ($)	Jun. 30, 2013 USD ($)	Dec. 31, 2010 USD ($) item	Jun. 30, 2016 USD ($)	Dec. 31, 2006 USD ($)
Collaborative Agreements disclosures
Amount of arrangement consideration included in license and milestone fees							$ 76,000	$ 10,077,000	$ 10,692,000	$ 6,070,000	$ 5,086,000	$ 5,078,000	$ 41,417,000	$ 6,234,000	$ 26,915,000	$ 57,815,000	$ 39,455,000
Costs related to the research and development services							38,652,000	$ 36,094,000	$ 38,199,000	$ 35,132,000	$ 30,437,000	$ 25,666,000	$ 27,647,000	$ 28,018,000	$ 148,077,000	111,768,000	106,958,000
Development and Commercialization License | Development milestones
Collaborative Agreements disclosures
Potential milestone payments																					$ 4,500,000
Novartis
Collaborative Agreements disclosures
Number of related targets | item															2
Payments received under collaboration agreement																				$ 60,200,000
Costs related to the research and development services															$ 67,000	141,000	1,400,000
Costs related to clinical materials sold															$ 0	644,000	1,300,000
Novartis | Right-to-test agreement
Collaborative Agreements disclosures
Number of single-target licenses | item						1													6
Number of related targets | item						2
Payments received under collaboration agreement					$ 5,000,000	$ 1,000,000													$ 45,000,000
Term of agreement					1 year														3 years
Payments for extension of agreement						3,500,000
Payments received under collaboration agreement in connection with amended agreement						3,500,000
Novartis | Development and Commercialization License
Collaborative Agreements disclosures
Number of single-target licenses | item			3
Payments received under collaboration agreement			$ 1,000,000	$ 1,000,000	$ 1,000,000														$ 1,000,000
Potential milestone payments			$ 199,500,000			199,500,000													199,500,000
Potential milestone payments under second option						$ 238,000,000
Estimated utilization period after commercialization															10 years
Discount rate (as a percent)															16.00%
Amount of arrangement consideration included in license and milestone fees																$ 25,700,000	17,200,000	$ 11,100,000
Cumulative catch-up amount included in license and milestone fees																	$ 1,000,000
Estimated term of development and commercialization license						25 years
Novartis | Development and Commercialization License | Development milestones
Collaborative Agreements disclosures
Payments received under collaboration agreement	$ 5,000,000	$ 5,000,000																		55,000,000
Potential milestone payments						$ 22,500,000													22,500,000
Potential milestone payments under second option						22,500,000
Novartis | Development and Commercialization License | Phase I clinical trial
Collaborative Agreements disclosures
Number of single-target licenses | item															4
Potential milestone payments							5,000,000								$ 5,000,000					5,000,000
Novartis | Development and Commercialization License | Phase II clinical trial
Collaborative Agreements disclosures
Number of single-target licenses | item															2
Potential milestone payments							$ 7,500,000								$ 7,500,000					7,500,000
Novartis | Development and Commercialization License | Future Technological Improvements
Collaborative Agreements disclosures
Payments received under collaboration agreement																				4,500,000
Novartis | Development and Commercialization License | Research Services
Collaborative Agreements disclosures
Payments received under collaboration agreement																				$ 710,000
Novartis | Development and Commercialization License | Regulatory milestones
Collaborative Agreements disclosures
Potential milestone payments						77,000,000													77,000,000
Potential milestone payments under second option						115,500,000
Novartis | Development and Commercialization License | Sales milestones
Collaborative Agreements disclosures
Potential milestone payments						100,000,000													$ 100,000,000
Potential milestone payments under second option						$ 100,000,000